{"entity":{"id":"huyabio","kind":"company","name":"HUYABIO International","aka":["HUYABIO International, LLC.","HUYA Bioscience International","HUYABIO"],"tldr":"HUYABIO is a San Diego company that licenses Chinese-discovered medicines for the rest of the world; its lead is tucidinostat, the oral HDAC inhibitor approved in China and Japan for T-cell lymphoma, which it took into a phase 3 trial in melanoma with a checkpoint inhibitor.","summary":"HUYABIO International, based in San Diego, in-licenses drug candidates from Chinese companies and develops them outside China. Its lead compound tucidinostat (HBI-8000, chidamide), a class I HDAC inhibitor approved in China for peripheral T-cell lymphoma and breast cancer and in Japan for lymphoma, was tested with nivolumab in the phase 3 trial registered on ClinicalTrials.gov under HUYABIO as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://huyabio.com"},{"label":"ClinicalTrials.gov: trials led by HUYABIO International, LLC.","url":"https://clinicaltrials.gov/search?lead=HUYABIO%20International%2C%20LLC."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q140045552"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["melanoma","peripheral-t-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["tucidinostat"],"companies":["chipscreen"],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://huyabio.com","stage":"private-large","investors":[],"funding":[]},"route":"/companies/huyabio/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"}],"drug":[{"id":"tucidinostat","kind":"drug","name":"Tucidinostat (chidamide)","route":"/drugs/tucidinostat/"}],"company":[{"id":"chipscreen","kind":"company","name":"Chipscreen Biosciences","route":"/companies/chipscreen/"}],"term":[{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/"},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/"}]}}